SACCARDI, RICCARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.941
EU - Europa 1.486
AS - Asia 504
AF - Africa 13
SA - Sud America 1
Totale 3.945
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.939
RU - Federazione Russa 737
IE - Irlanda 214
IT - Italia 188
SE - Svezia 156
SG - Singapore 142
CN - Cina 131
HK - Hong Kong 94
PL - Polonia 88
IN - India 59
JO - Giordania 41
CH - Svizzera 35
IR - Iran 21
FI - Finlandia 17
GB - Regno Unito 14
CI - Costa d'Avorio 13
DE - Germania 9
ES - Italia 8
KR - Corea 8
FR - Francia 7
UA - Ucraina 5
BE - Belgio 4
TR - Turchia 4
VN - Vietnam 4
AT - Austria 2
CA - Canada 2
NL - Olanda 2
CO - Colombia 1
Totale 3.945
Salva come PNG Salva come JPEG
Città #
Santa Clara 442
Dublin 214
Fairfield 188
Chandler 184
Singapore 120
Ashburn 109
Warsaw 88
Woodbridge 83
Altamura 71
Lawrence 71
Cambridge 69
Seattle 65
Hong Kong 64
Wilmington 64
Houston 56
Mumbai 49
Ann Arbor 47
Princeton 41
Beijing 38
Florence 37
Bern 35
Kent 34
Boston 33
Buffalo 28
Milan 21
Dearborn 19
New York 19
Moscow 17
Shanghai 16
Medford 14
Abidjan 13
San Diego 12
Los Angeles 10
Boardman 9
Barcelona 8
Falls Church 8
Yubileyny 8
Guangzhou 7
Norwalk 7
Seoul 7
Helsinki 6
Jacksonville 5
Pune 5
Tehran 5
Andover 4
Brussels 4
Dong Ket 4
Rome 4
West Jordan 4
Fuzhou 3
Hillsboro 3
Jinan 3
Kunming 3
Lappeenranta 3
Livorno 3
Aversa 2
Bremen 2
Frankfurt am Main 2
Hangzhou 2
Istanbul 2
Izmir 2
Kemerovo 2
Kilburn 2
Legnaro 2
London 2
Lyon 2
Nanchang 2
Nanjing 2
Palermo 2
Redmond 2
Romola 2
Taranto 2
Vienna 2
Wuhan 2
Zibello 2
Amsterdam 1
Arezzo 1
Bangalore 1
Bogotá 1
Castelliri 1
Chennai 1
Hefei 1
Heinrichsthal 1
Merate 1
Montespertoli 1
Montreal 1
Nembro 1
Olbia 1
Old Bridge 1
Paris 1
Phoenix 1
Pisa 1
Prato 1
Rui'an 1
San Mateo 1
Shenzhen 1
Taizhou 1
Vancouver 1
Washington 1
Xi'an 1
Totale 2.549
Salva come PNG Salva come JPEG
Nome #
A non-traditional approach to cryopreservation by ultra-rapid cooling for human mesenchymal stem cells 188
Bio-Engineered Mesenchymal Stromal Cell (MSCs) Grafts for Skin Repair/Regeneration. Preclinical Aspects 151
Therapeutic efficacy of autologous non-mobilized enriched circulating endothelial progenitors in patients with critical limb ischemia ― The scelta trial 150
The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies 138
Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation 126
MSCs seeded on bioengineered scaffolds improve skin wound healing in rats. 119
Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis. 113
Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients 112
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: The Italian multi-centre experience 108
Intravesical application of platelet-rich plasma in patients with persistent haemorrhagic cystitis after hematopoietic stem cell transplantation: a single-centre preliminary experience 104
Human mesenchymal stromal cells preserve their stem features better when cultured in the Dulbecco's modified Eagle medium. 96
The effects of Exendin-4 on bone marrow-derived mesenchymal cells. 96
Autologous Stem Cell Transplantation International Multiple Sclerosis (ASTIMS) trial: a randomised, phase II, controlled, multicentre trial 89
CMV AND EBV REACTIVATION AFTER AUTOLOGOUS HAEMOPOIETIC STEM CELL TRANSPLANTATION WITH BEAM CONDITIONING REGIMEN FOR MULTIPLE SCLEROSIS AND LYMPHOMA: A RETROSPECTIVE SINGLE CENTER CASE-CONTROL STUDY 88
Treatment of experimental esophagogastric myotomy with bone marrow mesenchymal stem cells in a rat model. 85
Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation 82
Efficacy of autologous hematopoietic stem cell transplantation in secondary progressive Multiple sclerosis 82
Mesenchymal Stem Cells and Autoimmune Diseases: The Case of Multiple Sclerosis 81
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis 80
Prevalence of disability improvement as a potential outcome for multiple sclerosis trials 78
AIDS patient with severe T cell depletion achieved control but not clearance of SARS-CoV-2 infection 76
Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. 76
HSCT for severe multiple sclerosis with BEAM/ATG: impact on female fertility 75
Management of viral reactivation in multiple sclerosis patients after autologous transplantation with BEAM/ATG conditioning regimen 74
CMV and EBV reactivation in autologous haemopoietic stem cell transplantation for severe multiple sclerosis 73
Neuropsychological assessment in aggressive multiple sclerosis treated with stem cell transplantation 72
Autologous hematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis 72
Reconstitution of natural or vaccination-driven immunity after aHSCT in multiple sclerosis 68
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience 68
Preliminary results of ASTIMS, a prospective randomised Phase II EBMT trial on autologous HSCT in poor prognosis Multiple Sclerosis 68
Long term follow-up of autologous stem cell transplantation (HSCT) for the treatment of secondary progressive multiple sclerosis: single centre experience 68
intermediate intensity regimen in autologous HSCT for severe Multiple Sclerosis: a a large, single center experience 66
Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor 66
Impact of new DMAs on the safety profile of patients undergoing autologous haematopoietic stem cell transplantation for Multiple Sclerosis 65
Safety profile of autologous haematopoietic stem cell transplantation following natalizumab therapy in aggressive forms of multiple sclerosis 65
DIFFERENCES IN MSCS IP-10 PRODUCTION BETWEEN MS PATIENTS AND HEALTHY DONORS 65
GENE EXPRESSION ANALYSIS OF PBMNC FROM MS PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION (HSCT) 62
Comparing human bone marrow mesenchymal stem cells isolated from MS patients with ND ones: possible impact on MS therapy and immunopathology 61
Purely myeloablative conditioning regimen in aggressive multiple sclerosis: two case reports 60
5-methyltetrahydrofolate (mTHF) induces monocytes differentiation in HL60 cells 57
Long-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications 57
Intermediate intensity regimen in autologous HSCT for severe multiple sclerosis: a large, single center experience 57
Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update 55
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis 53
Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis 52
Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation 49
Impact of autologous haematopoietic stem cell transplantation on fertility in aggressive multiple sclerosis 44
Long term outcomes after autologous hematopoietic stem cell transplantation for treatment of MS 43
Panel Session Report: Multiple Sclerosis 42
Should autologous hematopoietic stem cell transplantation be offered as a first-line disease modifying therapy to patients with multiple sclerosis? 28
The role of chemotherapy in hematopoietic stem cell transplantation for autoimmune disorders: From lymphoablative to myeloablative conditioning protocols 20
Totale 4.023
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.280
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.280
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020366 0 0 0 0 60 64 56 47 37 41 42 19
2020/2021241 27 24 8 35 22 16 13 14 22 36 15 9
2021/2022272 3 32 12 23 17 4 8 29 15 6 42 81
2022/2023891 55 197 61 35 60 140 115 61 90 0 35 42
2023/2024465 10 60 49 31 38 57 22 83 9 27 51 28
2024/20251.582 117 287 170 454 554 0 0 0 0 0 0 0
Totale 4.023